Inhibin B
Also known as: INHIBINB
Use
This test is employed to differentiate ovarian tumors that have normal CA 125 levels, specifically identifying them as stromal or mucinous epithelial tumors. It is also applicable for monitoring the recurrence of stromal ovarian tumors. The Inhibin B test is essential in the context of ovarian cancer biomarkers and plays a role in the diagnosis and management of certain ovarian tumor conditions.
Special Instructions
For premenopausal females, it is preferred to collect samples during the follicular phase of the menstrual cycle. Serum should be collected in a serum separator tube or plain red tube and transferred to an ARUP standard transport tube.
Limitations
Values obtained through this assay, performed using the ANSH ultra-sensitive Inhibin B ELISA kit, cannot be compared interchangeably with values obtained using different methodologies or kits. The test is a Laboratory Developed Test (LDT) and has not been cleared or approved by the US Food and Drug Administration, though it is performed in a CLIA certified laboratory. Grossly hemolyzed specimens, room temperature specimens, and plasma are unacceptable conditions for the specimen.
New York Approved
Methodology
Immunoassay (ELISA)
Biomarkers
LOINC Codes
- 34319-4
Result Turnaround Time
1-8 days
Related Documents
For more information, please review the documents below
Specimen
Serum
Volume
0.5 mL
Minimum Volume
0.2 mL
Container
ARUP standard transport tube
Collection Instructions
Collect in serum separator tube or plain red. Transfer serum to an ARUP standard transport tube.
Patient Preparation
Preferred collection during the follicular phase for premenopausal females.
Causes for Rejection
Room temperature specimens, grossly hemolyzed specimens, plasma.
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | Unacceptable |
| Refrigerated | 72 hours |
| Frozen | 1 month |